This program highlights the essential role of shared decision-making (SDM) and motivational interviewing in caring for individuals with or at risk for hepatitis B (HBV), hepatitis C (HCV), and hepatitis D (HDV). Moving beyond traditional paternalistic models of care, SDM …
Latine patient populations represent a rapidly growing and diverse segment of the U.S. healthcare landscape. Cultural beliefs, traditional healing practices, community influences and variable levels of trust in the healthcare system can significantly influence attitudes toward illness, medication use, and …
When adopting a comprehensive approach to improving the health of patients with idiopathic hypersomnia (IH) or narcolepsy, it is essential for clinicians to consider the interplay between cardiometabolic (CM), neurologic, and psychiatric comorbidities. Clinicians must prioritize educating both themselves and …
Obesity affects more than 44% of post-9/11 U.S. Veterans—far surpassing rates in the general population—and contributes substantially to cardiometabolic disease, osteoarthritis, chronic pain, sleep apnea, and type 2 diabetes. Despite strong evidence supporting effective treatments, clinical uptake remains suboptimal. Fewer …
This global discussion among experts in Asia, Europe, and North America focuses on reducing delays in treatment for hepatitis B (HBV), hepatitis C (HCV), and hepatitis D (HDV) by addressing current gaps in screening, including the underuse of evidence-based diagnostic …
Patients living with primary immunodeficiency (PI) disorders face prolonged or severe infections that pose significant challenges to daily life. While infectious PI phenotypes have garnered the most visibility, this focus has left noninfectious variants underrecognized and delayed in diagnosis, leading …
Despite major advances in inflammatory bowel disease (IBD) management, real-world data show that many patients continue to experience suboptimal outcomes due to misaligned treatment goals, therapeutic inertia, and limited integration of novel therapies, particularly IL-23 inhibitors—into individualized care plans. While …
Despite major advances in inflammatory bowel disease (IBD) management, real-world data show that many patients continue to experience suboptimal outcomes due to misaligned treatment goals, therapeutic inertia, and limited integration of novel therapies, particularly IL-23 inhibitors—into individualized care plans. While …
Primary Immunodeficiency (PI) disorders are a group of more than 180 inherited disorders, of the approximately 550 inborn errors of immunity (IEIs), that predispose affected patients to a variety of bacterial, viral, and fungal infections. Infections may be more prolonged …